
Anne Llewellyn had been a nurse in the Emergency Department and Respiratory Intensive Care for almost 40 years when she was diagnosed with a central nervous system brain tumor.
Anne Llewellyn had been a nurse in the Emergency Department and Respiratory Intensive Care for almost 40 years when she was diagnosed with a central nervous system brain tumor.
The FDA has approved ClearLLab multicolor reagents for the detection of chronic leukemia, acute leukemia, non-Hodgkin lymphoma, multiple myeloma, myelodysplastic syndrome and myeloproliferative neoplasms.
A trial testing the combination of ublituximab, ibrutinib, and umbralisib showed that the combination was well tolerated and had activity across patients with high-risk B-cell malignancies.
The abilities of the caregiver of a patient with glioblastoma multiforme may affect that patient's survival.
Jennifer Ligibel, MD, discusses Breast Cancer Weight Loss Study and how a weight loss intervention may help patients with breast cancer.
Researchers found that the rate of suicide in patients with lung cancer is much higher than those with other types of cancer.
There are specific challenges when treating AYA patients with Hodgkin lymphoma.
Among long-term CRC survivors, regular use of aspirin is associated with overall survival and use of NSAIDs was significantly associated with improved survival only in individuals with KRAS wild-type tumors.
The Biden Cancer Initiative has named Kim Thiboldeaux, the CEO of Cancer Support Community, to its Board of Directors.
A recent study has shown that the cancer risks for women with BRCA1 and BRCA2 mutations depend on the extent of the woman’s family history of cancer and the position of the specific fault within the gene.
The FDA has approved the dabrafenib/trametinib combination for patients with BRAF V600-positive advanced or metastatic non-small cell lung cancer (NSCLC)
As the Senate revealed their healthcare reconciliation bill, healthcare advocacy and profession organizations weighed in.
The FDA has approved subcutaneous rituxumab (Rituxan Hycela) for the treatment of adults with previously untreated
The use of standard criteria for palliative care consultations in patients with advanced cancer is associated with an improvement in the quality of oncology care, as well as a reduction in downstream healthcare utilization.
The Insitute for Clinical Immuno-Oncology (ICLIO) are supporting multidisciplinary cancer teams to better deliver new and emerging cancer therapies.
The Association of Community Cancer Centers has lauched a financial advocacy boot camp offering free comprehensive online training for oncology financial advocates.
National Leiomyosarcoma Foundation joins Pattern.org in an effort to collect tumor tissue form patients with rare cancers.
National Leiomyosarcoma Foundation has collaborated to bring resources to family, caregivers and patients with leiomyosarcoma.
Regina Cunningham, PhD, RN, NEA-BC, FAAN, discusses her career journey, which led her to become CEO of the Hospital of the University of Pennsylvania, and shares insights on how nurses can leverage their unique skills to assume leadership roles in healthcare.
ASCO has released its Clinical Practice Guidelines as an app so clinicians can keep important information at their fingertips.
Daratumumab (Darzalex) has been approved for use in combination with pomalidomide (pomalyst) and dexamethasone for patients with multiple myeloma.
Expert Ilana Cass, MD, explains the options that women with have when it comes to preventing ovarian cancer.
Communication is key when it comes to discussing genetic information and hereditary cancers with family members.
A recent study looked at the long-term health-related effects of treatment for patients with localized prostate cancer, finding that some can continue for more than 10 years after treatment.
Adjuvant pertuzumab may help some early breast cancer patients.
Jonathan E. Rosenberg, MD, medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the new treatment guidelines for patients with non-metastatic muscle invasive bladder cancer.
The PARP inhibitor olaparib (Lynparza) was shown to reduce the risk of disease progression by 42% compared to standard chemotherapy in patients with BRCA-positive, HER2-negative breast cancer.
A recent study has found that a topical nail bed balm may be effective in preventing and mitigating nail damage, a common adverse effect from taxane chemotherapy.